metastatic setting

Another trial, entitled the Triple Negative Trial, is evaluating carboplatin against docetaxel in the metastatic setting.

P53 mutations in the primary prostate cancer are relatively low and are more frequently seen in metastatic settings, hence, p53 mutations are late event in pathology of prostate cancer.